Efpia
The European Federation of Pharmaceutical Industries and Associations (EFPIA), headquartered in Belgium, represents the pharmaceutical industry across Europe. Founded in 1978, EFPIA plays a pivotal role in advocating for the interests of its members, which include leading pharmaceutical companies and national associations. The organisation focuses on key areas such as research and development, access to medicines, and healthcare policy. With a commitment to innovation, EFPIA supports initiatives that enhance patient access to high-quality treatments while promoting sustainable healthcare systems. Its unique position as a bridge between the pharmaceutical industry and European policymakers enables it to influence critical discussions on health and medicine. Notable achievements include significant contributions to public health and the advancement of regulatory frameworks that benefit both patients and the industry.
DitchCarbon Score
How does Efpia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Efpia's score of 36 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Efpia's reported carbon emissions
In 2022, Efpia reported significant carbon emissions totalling approximately 89,000,000 kg CO2e for Scope 1, about 4,900,000 kg CO2e for Scope 2, and around 97,100,000 kg CO2e for Scope 3, highlighting the substantial impact of their operations on global greenhouse gas emissions. Efpia has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions by 46% by 2030, using a 2019 baseline. This interim target is part of a longer-term goal to achieve a 95% reduction by 2040. These targets reflect Efpia's commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical industry. Additionally, Roche, a member of Efpia, has reported a 45% reduction in greenhouse gas emissions from 2009 to 2019 and aims for a further 75% reduction from 2019 to 2029. These initiatives underscore the industry's focus on sustainability and the transition towards a low-carbon economy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 8,900,000,000 |
| Scope 2 | 4,900,000,000 |
| Scope 3 | 97,100,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Efpia is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
